Chronic Subdural Hematoma: Why It Occurs and How It Is Treated
A minor bump to the head does not always seem like a serious event. But sometimes, several weeks later, a person develops a headache, unsteadiness, or unusual drowsiness. The cause may turn out to be a chronic subdural hematoma — a collection of blood and fluid beneath the dura mater.
This condition most often affects older adults. Its hallmark is that the hematoma can grow slowly, and the link between symptoms and a long-past injury is not always obvious. At the same time, modern research shows that the problem is not only about a one-time bleed. A prolonged process of inflammation and formation of fragile vessels can be sustained around the hematoma.
What Happens Inside the Skull
The brain is surrounded by several membranes. One of them is the dura mater. When tissues near it are damaged, a cavity can form between the membranes, where blood and other fluid accumulate. If the collection persists and develops gradually, it is called a chronic subdural hematoma, or CSDH.
The triggering event is often a fall or a blow to the head. However, the injury can be so minor that the person does not remember it. Sometimes no clear cause can be identified.
The risk of CSDH is increased by:
- older age;
- reduced brain volume, which makes the vessels between the brain and its membranes more vulnerable to stretching;
- use of anticoagulants and antiplatelet agents — drugs that reduce the blood's ability to clot;
- repeated falls and certain co-existing conditions.
The presence of risk factors does not mean that a hematoma will necessarily develop, but it helps the physician assess the likelihood of the disease.
Why the Hematoma Can Grow
CSDH used to be often described as a passive collection of old blood. Today, researchers view it as a more complex process.
After tissue damage, inflammation develops in the area of the hematoma. Thin membranes may form around the accumulated fluid. New blood vessels appear in the outer membrane, but their walls are often fragile and permeable. Because of this, fluid and small amounts of blood can re-enter the hematoma cavity.
At the same time, processes that break down formed blood clots intensify within it. As a result, fresh bleeding may be harder to stop.
This creates a kind of vicious circle: inflammation promotes the formation of fragile vessels, and repeated microbleeds sustain inflammation and hematoma growth. This is one reason why it sometimes enlarges long after the initial injury and can recur after treatment.
Symptoms That Should Raise Concern
Manifestations depend on the size of the hematoma, its rate of growth, and which parts of the brain it compresses. Possible symptoms include:
- worsening headache;
- weakness or numbness in the arm and leg, especially on one side;
- impaired balance and gait, more frequent falls;
- drowsiness, slowed responses, or confusion;
- worsening memory and attention;
- speech disturbances;
- in severe cases — loss of consciousness.
In an older person, gradual forgetfulness or unsteadiness can easily be mistakenly attributed to age. Therefore, new or worsening symptoms warrant medical evaluation, especially after a fall or blow to the head.
If sudden weakness in the limbs, speech disturbance, marked drowsiness, loss of consciousness, or severe worsening headache occurs, emergency medical services must be called. These signs can accompany not only a hematoma but also a stroke or other dangerous condition.
Why Old Age Is the Main Risk Factor
CSDH is primarily a disease of older adults, and there are several explanations for this. With age, the brain slightly decreases in volume (atrophy), increasing the space between the skull and the brain — blood and fluids accumulate more easily, and the veins become longer and more vulnerable. But it is not only about anatomy. The aging process itself — the so-called “inflammaging” — directly engages every “mechanism” of the vicious cycle: it increases the activity of enzymes that stimulate vessel growth, shifts the balance of signaling molecules toward “leakiness” and instability, and weakens the antioxidant defense of cells. In effect, the aging body itself creates ideal conditions for triggering and sustaining CSDH.
How the Hematoma Is Detected
Computed tomography (CT) is the fast, accessible, and reliable first-line method. On the scan, CSDH usually appears as a dark crescent-shaped area between the skull and the brain. A key sign: the hematoma can cross cranial sutures (unlike an epidural hematoma, which is confined by bony structures). CT helps assess the scale of the problem: whether central brain structures are shifted, whether the ventricles are compressed — these are critical parameters for deciding on emergency surgery. About 20% of hematomas are bilateral, which can “mask” the shift of the brain. Contrast agent is used to refine the diagnosis: the outer neomembrane lights up brightly — a sign of an active process.
Magnetic resonance imaging (MRI) is the “second opinion” for complex cases. It takes longer and costs more, but it sees soft tissues significantly better. MRI can detect internal septa within the hematoma (in 74% of cases), which is important for choosing the surgical technique; identify signs of fresh bleeding (through diffusion sequences); and distinguish CSDH from a tumor, abscess, or another type of hematoma. Special sequences visualize hemosiderin — a breakdown product of blood that is usually present in CSDH but absent in a similar condition, the hygroma.
Beyond imaging, the physician evaluates consciousness, limb strength, speech, and other functions. Special scales exist to describe the severity of the condition, including the Markwalder scale. However, no scale on its own replaces examination and an individual decision about treatment.
When to Observe and When Surgery Is Needed
Not every chronic hematoma must be removed immediately. If there are no symptoms or they are minimal, and the condition and imaging allow it, the physician may offer observation. This includes follow-up examinations and, if necessary, a control CT.
Some small hematomas shrink on their own over time. But this cannot be reliably predicted in advance: if symptoms worsen or the hematoma grows, the approach is reconsidered.
With pronounced symptoms, worsening condition, or significant compression of the brain, surgical treatment is often required. The decision is made considering not only the size of the hematoma but also the patient's overall condition, age, co-existing diseases, and medications taken.
Removal Through a Small Hole
One of the most common treatment methods is creating one or several small holes in the skull, through which the contents of the hematoma are removed. After that, a drain — a thin tube to remove remaining fluid — is often placed for a short time. Drainage reduces the likelihood of the hematoma reaccumulating.
If there are complex septa or dense areas inside the hematoma, the neurosurgeon may choose a different surgical approach. The choice depends on the specific situation.
Embolization: Targeting the Blood Supply
A newer method is embolization of the middle meningeal artery. A thin catheter is inserted through a vessel and material is delivered that blocks blood flow in the branches of the artery supplying the membranes of the hematoma.
Unlike surgery to remove the contents, embolization does not relieve brain compression immediately. Its task is to reduce the blood supply to the fragile vessels and thereby help prevent the growth or recurrence of the hematoma.
Clinical studies have shown benefit of this method for some patients, including in combination with surgery, although results of individual studies differ. Embolization is not suitable for everyone and also carries risks. With dangerous compression of the brain, it does not necessarily replace urgent surgical treatment.
Do Medications Help?
Researchers are studying drugs that could affect inflammation, vessel formation, or clot breakdown inside the hematoma. However, drug therapy is not yet a universal replacement for surgery.
- Dexamethasone. Despite its anti-inflammatory action and a possible reduction in the number of repeat operations in some studies, its use did not improve overall functional outcomes and was accompanied by serious side effects. Therefore, routine use in CSDH is not recommended.
- Atorvastatin. Its possible benefit continues to be studied, but there is not yet convincing evidence to consider it a standard treatment for CSDH.
- Tranexamic acid. The drug affects the breakdown of blood clots and is considered a potential treatment option. However, its efficacy and safety in CSDH require further clarification.
Particular attention is needed for the use of anticoagulants and antiplatelet agents. Stopping them may reduce the risk of bleeding, but at the same time increase the risk of stroke or thrombosis. Such drugs must not be stopped or resumed on one's own: the decision is made by the physician individually.
What Happens After Treatment
After the hematoma is removed, the condition of many patients improves, but recovery may take time. Some need help returning to walking and daily activities, balance exercises, or assessment of memory and attention.
An important part of follow-up is timely detection of a recurrence, that is, reaccumulation of the hematoma. The risk varies across patients and depends, among other things, on the characteristics of the hematoma and the treatment method. If after discharge headache, weakness, drowsiness, confusion, or unsteadiness reappear or worsen, medical help must be sought.
In some people, cognitive and physical difficulties persist even after a technically successful operation. Age, co-existing diseases, and the patient's level of independence also affect long-term condition. Therefore, recovery does not end with discharge from the hospital: sometimes extended work with physicians and rehabilitation specialists is needed.
The Bottom Line
Chronic subdural hematoma is not simply an “old bruise” inside the skull. It is a condition that can gradually progress due to inflammation and repeated microbleeds. CT helps quickly detect the hematoma and assess brain compression, and treatment ranges from observation to surgery and, in selected cases, embolization.
MSCT scan of the brain in a 92‑year‑old patient. Chronic subdural hematoma in the left hemisphere.
Postoperative MSCT of the brain in a 92‑year‑old patient: a drain was placed in the subdural space, the volume of the subdural hematoma decreased significantly, and the dislocation of the midline structures regressed.
MSCT of the brain in a 72‑year‑old patient. Chronic subdural hematoma in the left hemisphere, dislocation of the midline structures of the brain to the right.
Control MSCT scan of the brain in a 72‑year‑old patient, 10 days after surgery.
MRI of the brain in a 71‑year‑old patient. Chronic subdural hematoma in the right hemisphere.
Control MSCT scan of the brain in a 71‑year‑old patient after surgery: condition after drainage of a subdural hematoma.
MSCT of the brain in a 69‑year‑old patient: chronic subdural hematoma in the left hemisphere.
Control MSCT of the brain in a 69‑year‑old patient before discharge for outpatient treatment.